Why did Amgen's operating profit fluctuate in recent quarters?

Amgen's operating profit has experienced a significant increase from the previous quarter's $1.0 billion to the current quarter's $1.56 billion, which is a 247.56% growth. 1. **Volume Growth of Product Sales**: The primary driver of the revenue growth is the 23% increase in product volume sales. This is evident in the performance of key products such as Repatha, TEZSPIRE, EVENITY, and BLINCYTO, which have delivered substantial sales growth. 2. **Global Performance**: The growth is not limited to a single region; rather, it is attributed to strong global performance across different therapeutic areas. This indicates a diversified and robust market presence, which is a positive indicator for future earnings stability. 3. **Strategic Investments**: The company's investment in its rapidly advancing pipeline and the delivery of innovative therapies across its four therapeutic areas is a strategic move that could lead to future revenue growth. This suggests that the current operating profit fluctuation may be a result of the company's proactive investment in growth opportunities. In conclusion, Amgen's operating profit has shown a significant upward trend due to a combination of factors including volume growth of product sales, strong global performance, and strategic investments. These factors indicate a positive outlook for the company's future earnings.